Modulating the hormonal environment in which endometrial cancers grow could make tumors significantly more sensitive to a new class of drugs known as PARP inhibitors, a researcher at UCLA’s Jonsson Comprehensive Cancer Center has shown for the first time. The findings could lead to a novel one-two punch therapy to fight endometrial cancers and provide an alternative option for conventional treatments that, particularly in advanced disease, have limited efficacy. Read more here.
Study mentioned: Janzen DM, et al. Low Levels of Circulating Estrogen Sensitize PTEN-null Endometrial Tumors to PARP Inhibition In Vivo. Mol Cancer Ther. 2013 Nov 12. [Epub ahead of print] PMID: 24222661
No comments:
Post a Comment